Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00

Pharming Group (NASDAQ:PHAR)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $10.00, but opened at $9.79. Pharming Group shares last traded at $9.59, with a volume of 617 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Price Performance

The company has a debt-to-equity ratio of 0.62, a current ratio of 4.06 and a quick ratio of 3.33. The business has a 50 day moving average of $10.63 and a 200 day moving average of $11.35. The company has a market cap of $637.55 million, a PE ratio of -68.71 and a beta of 0.20.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. The company had revenue of $81.20 million for the quarter, compared to the consensus estimate of $71.83 million. As a group, research analysts predict that Pharming Group will post -0.02 EPS for the current year.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC bought a new stake in shares of Pharming Group (NASDAQ:PHAR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,715 shares of the company’s stock, valued at approximately $134,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.